Computerized clinical decision support systems, or CDSS, represent a paradigm shift in
healthcare today. CDSS are used to augment clinicians in their complex decision-making …

Background & Aims The medical management of ulcerative colitis (UC) has improved through
the development of new therapies and novel approaches that optimize existing drugs. …

The demonstration that immune and epithelial cells can discriminate between different
microbial species has extended our understanding of the actions of probiotics beyond simple …

Background Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective
maintenance therapy for patients with Crohn's disease without fistulas. It is not known …

Background & Aims: Tumor necrosis factor blockade has been shown to be an effective
treatment strategy in Crohn’s disease (CD). Adalimumab is a human immunoglobulin G1 (IgG 1 ) …

Background The efficacy of vedolizumab, an α 4 β 7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials, we …

… RN Fedorak4, … R Panaccione7, … 18.den Broeder A, van de Putte L, Rau R, et al. A single
dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody …

Background Although corticosteroids are highly effective in improving symptoms of Crohn's
disease, they may have substantial toxicity. In some patients, attempts to discontinue …

METHODS Thirty-four ambulatory patients with active UC received open label VSL# 3,
3,600 billion bacteria daily in two divided doses for 6 wk. The presence of biopsy-associated …

Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA),
a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the …